RESUMO
Eighteen patients (11 men and 7 women) suffering from primary or secondary gout, were treated with either proquazone or indomethacin for acute attacks in a double-blind study. There were 9 patients in each treatment group. A marked improvement of clinical symptoms appeared in 2-3 days. In the proquazone group, complete remission was achieved in 6 patients, a good result in one, and a slight improvement in one patient, whereas one patient did not respond to treatment. The corresponding figures for the indomethacin group were 4 cases with complete remission, 4 with a good result, and one not responding to treatment. A significant decrease in s-uric acid values was noted in the proquazone group. In this group too, mild gastrointestinal symptoms appeared in 2 patients.
Assuntos
Anti-Inflamatórios/uso terapêutico , Artrite/tratamento farmacológico , Gota/tratamento farmacológico , Indometacina/uso terapêutico , Quinazolinas/uso terapêutico , Doença Aguda , Adulto , Idoso , Artrite/complicações , Ensaios Clínicos como Assunto , Método Duplo-Cego , Avaliação de Medicamentos , Feminino , Gota/complicações , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
The efficacy and tolerance of proquazone, 900 mg, and ibuprofen, 1200 mg, were compared in a randomized, double-blind clinical trial of 6 months' duration, with 44 patients, 21 on proquazone and 23 on ibuprofen. Comparison of proquazone-treated patients with patients treated with iburofen showed a significantly better improvement , as is demonstrated by the significant differences in the Lansbury Index, in nocturnal pain, final assessment of therapeutic effect, and number of interruptions due to lack of efficacy. All differences were in favour of proquazone, proving its therapeutic superiority over ibuprofen. The side effects in the proquazone group were mainly gastrointestinal, and 2 patients broke off treatment prematurely due to diarrhoea (in one patient, lack of efficacy was a contributory cause). A third patient discontinued because of moderate nausea and dizziness. In the ibuprofen group, 4 patients discontinued because of side effects (skin eruptions, dizziness, epigastric discomfort, and one thrombocytopenia) in addition to lack of efficacy. Proquazone seems to be an effective and well tolerated anti-inflammatory analgesic.
Assuntos
Anti-Inflamatórios/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Ibuprofeno/uso terapêutico , Quinazolinas/uso terapêutico , Adulto , Idoso , Anti-Inflamatórios/efeitos adversos , Ensaios Clínicos como Assunto , Método Duplo-Cego , Avaliação de Medicamentos , Feminino , Humanos , Ibuprofeno/efeitos adversos , Masculino , Pessoa de Meia-Idade , Quinazolinas/efeitos adversos , Fatores de TempoRESUMO
The accumulation of Tc-99m in knee and finger joints was studied in 41 rheumatic patients and 25 controls. The accumulation of the radioisotope was correlated with the intensity of active inflammation. Rheumatoid joints showed a stronger Tc-99m uptake than joints with osteoarthritis. There was some overlap, however, which limits the value of the method. The effect of local and systemic anti-rheumatic treatments could be followed with joint scanning. Radioactivity was also measured in the synovial fluid but this fraction of the Tc-99m was not large. The synovial fluid radioactivity tended to increase as the Tc-99m accumulation in the knee area decreased. Accumulation of Tc-99m in joints is regarded as principally due to the enhanced circulation in inflamed joint tissues.
RESUMO
Erbium--169 was compared with triamcinolone hexacetonide in the topical treatment of 32 patients suffering from rheumatoid arthritis. Erbium--169 was injected into 83 and triamcinolone hexacetonide into 54 proximal interphalangeal or metacarpophalangeal joints. Both treatments produced alleviation of joint pain and swelling and improvement of grip strength. At every check-up (1--18 months) the percentage of remissions was higher after triamcinolone hexacetonide injection than after erbium--169. The difference was significant at 1, 3, and 6 months.